A Drug That Improves Exercise Capacity by a Greater Percentage Than Tracleer Would Earn a 48 Percent Patient S Gleevec Will Achieve Clinical Gold Standard Status by 2011, According to a New Report from Decision Resources WALTHAM, Mass., July 22, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing...
A drug that improves exercise capacity by a greater percentage than Tracleer would earn a 48 percent patient s Gleevec Will Achieve Clinical Gold Standard Status by 2011, According to a New Report from Decision Resources WALTHAM, Mass.- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and...
A Drug That Improves Exercise Capacity by a Greater Percentage Than Tracleer Would Earn a 48 Percent Patient S Gleevec Will Achieve Clinical Gold Standard Status by 2011, According to a New Report from Decision Resources WALTHAM, Mass., July 22, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing...
UPDATE 1-Actelion Q2 profit falls 19 pct, raises forecast ZURICH, July 22 (Reuters) - Swiss biotechnology company Actelion Ltd <ATLN.VX> posted a 19 percent drop in second-quarter net profit on Tuesday, hit by higher research costs and the weak dollar, and raised its full-year forecast.
UPDATE 1-Actelion Q2 profit falls 19 pct, raises forecast ZURICH, July 22 (Reuters) - Swiss biotechnology company Actelion Ltd (News) <ATLN.VX> posted a 19 percent drop in second-quarter net profit on Tuesday, hit by higher research costs and the weak dollar, and raised its full-year forecast...
UPDATE 1-Actelion Q2 profit falls 19 pct, raises forecast ZURICH, July 22 (Reuters) - Swiss biotechnology company Actelion Ltd <ATLN.VX> posted a 19 percent drop in second-quarter net profit on Tuesday, hit by higher research costs and the weak dollar, and raised its full-year forecast.
UPDATE 1-Actelion Q2 profit falls 19 pct, raises forecast ZURICH, July 22 (Reuters) - Swiss biotechnology company Actelion Ltd (ATLN.VX: Quote, Profile, Research) posted a 19 percent drop in second-quarter net profit on Tuesday, hit by higher research costs and the weak dollar, and raised its full...
A Drug That Improves Exercise Capacity by a Greater Percentage Than Tracleer Would Earn a 48 Percent Patient S Press Release Normal Version WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that improves exercise...
Actelion Announces Half Year Financial Results 2008 million - Product sales up 18 percent in local currencies compared to H1 2007 - Tracleer sales of CHF 605.2 million - Cash EBIT of CHF 190.8 million - Multiple Phase III studies on track - Substantial impact from Actelion/GSK orexin...
Actelion's Bosentan gets approval for PAH treatment in Vietnam Pulmonary Arterial Hypertension (PAH) sufferers in Vietnam now have access to a novel therapeutic option following the approval by the Ministry of Health of Bosentan (Tracleer), a drug for treatment of PAH.Bosentan, developed by...
GSK to pay Actelion up to $3.3 bln for drug rights ZURICH (Reuters) - GlaxoSmithKline Ltd could pay Swiss company Actelion Ltd up to 3.3 billion Swiss francs ($3.28 billion) to develop a promising insomnia drug in the largest biotech partnering deal.Glaxo, Europe's biggest drugmaker, beat...
PRESS RELEASE: Actelion And GlaxoSmithKline Enter Into Exclusive Collaboration To Realise The Full Potential O Corporate news announcement processed and transmitted by Hugin ASA.The issuer is solely responsible for the content of this announcement.
=--------------------------------------------------------------------- =------------- Actelion and...
GSK to pay Actelion up to $3.3 bln for drug rights ZURICH (Reuters) - GlaxoSmithKline Glaxo, Europe's biggest drugmaker, beat many of the world's top pharmaceuticals companies to partner Actelion's sleeping pill almorexant and the deal sent the Swiss biotech's stock soaring nearly 10 percent...
GSK to pay Actelion up to 1.6 bln for drug rights ZURICH: GlaxoSmithKline could pay Swiss company Actelion up to 3.3 billion Swiss francs (1.6 billion pounds) to develop a promising insomnia drug in the largest biotech partnering deal.Glaxo, Europe's biggest drugmaker, beat many of the...
GSK in insomnia drug deal with Actelion ZURICH (Reuters) - Europe's biggest drugmaker GlaxoSmithKline could pay up to 3.3 billion Swiss francs (1.6 billion pounds) for a licensing deal on a promising insomnia drug from Swiss company Actelion.Glaxo beat many of the world's...
GSK in insomnia drug deal with Actelion Glaxo beat many of the world's largest pharmaceuticals companies to partner Actelion's experimental sleeping pill almorexant and the deal sent the Swiss biotech's stock soaring nearly 10 percent on Monday.'The deal terms already allow...
UPDATE: Actelion In Pact With GlaxoSmithKline For Almorexant ZURICH -(Dow Jones)- Actelion Ltd (ATLN.VX) said Monday it has signed an agreement with GlaxoSmithKline (GSK) that gives the latter the exclusive worldwide rights for almorexant, a sleeping drug in development by the Swiss pharmaceutical...
2ND UPDATE: Actelion In Pact With GSK For Almorexant (Adds analyst, company comment)ZURICH -(Dow Jones)- Actelion Ltd (ATLN.VX) said Monday it has signed an agreement with GlaxoSmithKline (GSK) that gives the latter the exclusive worldwide rights for almorexant, a sleeping drug in development...
UPDATE 1-Actelion, GSK in $3.3 bln deal on almorexant ZURICH, July 14 (Reuters) - Swiss biotech firm Actelion (ATLN.VX: Quote, Profile, Research) teams up with British group GlaxoSmithKline(GSK.L: Quote, Profile, Research) to develop and market the Swiss firm's sleep medicine almorexant, in a...
The Early Show to profile Saginaw Township youth and his family His story of survival began when he received a lung transplant in November 2006 at Children's Hospital of Philadelphia.Doctors had diagnosed him at age 3 with pulmonary hemosiderosis, a rare disease that causes bleeding in the lungs.
'The Early Show' to profile Saginaw Township youth and his family His story of survival began when he received a lung transplant in November 2006 at Children's Hospital of Philadelphia.Doctors had diagnosed him at age 3 with pulmonary hemosiderosis, a rare disease that causes bleeding in the lungs.
Actelion to Join the SMI (Swiss Market Index) - Actelion Ltd (SWX: ATLN) announced today that the Management Committee of the SWX Swiss Exchange has decided to add Actelion shares (ATLN, CH001053248) to the Swiss Market Index SMI.Actelion shares will trade for the first time as part...
Bosentan receives positive EU opinion for treatment of patients with mildly symptomatic WHO functional Class I ALLSCHWIL, Switzerland - Actelion Ltd (SWX: ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion for bosentan (...
Actelion's Tracleer shows benefit in FC II PAH _ Actelion's Tracleer shows benefit in FC II PAH.
Actelion Pharmaceuticals Ltd - Bosentan receives positive EU opinion ctelion Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion for bosentan (Tracleer) to extend its use in Pulmonary...
